Spectranetics considers laser angioplasty for AMI (acute myocardial infarction) patients
This article was originally published in Clinica
Spectranetics says it is considering whether to ask the FDA for permission to remove the acute myocardial infarction (AMI) contraindication from its excimer laser angioplasty label.
You may also be interested in...
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.